AVTX (Avalo Therapeutics) NonCurrent Deferred Liabilities: $0.45 Mil (As of Mar. 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $19.25
GF Value $0.03
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Avalo Therapeutics NonCurrent Deferred Liabilities?

Avalo Therapeutics AVTX -3.61% 23 NonCurrent Deferred Liabilities is $0.45 Mil as of Mar. 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Avalo Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.45 Mil.

Avalo Therapeutics NonCurrent Deferred Liabilities Related Terms

Avalo Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics NonCurrent Deferred Liabilities Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.14 0.16 0.27 0.43

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.29 0.30 0.43 0.45
AVTX
23GF Score
Avalo Therapeutics Inc AVTX
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.45 Mil mean?
Avalo Therapeutics (AVTX) has a NonCurrent Deferred Liabilities of $0.45 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Avalo Therapeutics and its competitors.
Is Avalo Therapeutics' NonCurrent Deferred Liabilities too high?
Avalo Therapeutics' current NonCurrent Deferred Liabilities is $0.45 Mil. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' NonCurrent Deferred Liabilities compare to SANA and ANRO?
Avalo Therapeutics' NonCurrent Deferred Liabilities of $0.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current NonCurrent Deferred Liabilities is $0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $19.25 — trading 64066.7% above its estimated fair value. The current NonCurrent Deferred Liabilities is $0.45 Mil. Avalo Therapeutics' overall GF Score™ is 23/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current NonCurrent Deferred Liabilities is $0.45 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $19.25 is trading 64066.7% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • NonCurrent Deferred Liabilities: $0.45 Mil
  • GF Value™: $0.03 vs. price of $19.25 (64066.7% above fair value)
  • GF Score™: 23/100 with 8 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.25
Price
$0.03
GF Value